Who Paid My Doc
Charles Marquardt
Vascular Surgery Coon Rapids, MN Medical Doctor
NPI 1477180115 CMS profile 11289235
4040 Coon Rapids Blvd Nw Ste 120, Coon Rapids, MN 55433
General payments
$3,828
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Charles Marquardt of Coon Rapids, MN is reported in the CMS Open Payments database as having received $3,828 across 43 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 43rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,716 | 18 | |
| 2024 | General | $1,134 | 11 | |
| 2023 | General | $265 | 3 | |
| 2022 | General | $245 | 5 | |
| 2021 | General | $468 | 6 |
Beside peers
- Charles Marquardt
- Vascular Surgery median
- Middle half of Vascular Surgery
- National median
In program year 2025, general payments to Charles Marquardt were reported at $1,716. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.
Show as a table
| Year | Charles Marquardt | Vascular Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $796 | $226–$2,363 | $163 |
| 2020 | $0 | $348 | $118–$1,110 | $114 |
| 2021 | $468 | $471 | $158–$1,421 | $132 |
| 2022 | $245 | $725 | $222–$2,183 | $149 |
| 2023 | $265 | $836 | $257–$2,440 | $160 |
| 2024 | $1,134 | $909 | $252–$2,619 | $164 |
| 2025 | $1,716 | $924 | $273–$2,636 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
81
Drug cost
$441
Branded share of claims
84%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 56 | $309 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 12 | $80 | |
| Oxycodone Hcl | Generic | 13 | $53 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 200 Part D prescribers listed as Surgery; they describe a distribution and say nothing about conduct.
Records
43 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Vascular Surgery in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Vascular Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.